SAN DIEGO – Hillhurst Biopharmaceuticals, Inc. (“Hillhurst”), a clinical-stage biopharmaceutical company focused on developing oral therapies enabling the therapeutic use of low dose carbon monoxide (CO), today announced that the company has received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) permitting the company to...
Latest News
REDWOOD CITY, Calif. — Hinge Bio, Inc., a privately-held clinical-stage biotechnology company focused on the discovery and development of innovative antibody therapeutics, referred to as “GEM-DIMERs™”, announced the successful dosing of the first participants in one of its Phase 1 clinical trials of HB2198, the Company’s lead multispecific product candidate targeting...
Hiroshima, Japan – A team of researchers from Hiroshima University has discovered a molecule that promotes the production of cancer cells. This molecule may prove to be a potential therapeutic target in the treatment of triple-negative breast cancer, an aggressive form of breast cancer. Their work was published in the...
EB Research Partnership (“EBRP”) invested in the work that led to ZEVASKYN at Stanford University under their pioneering Venture Philanthropy Model. This approval marks a historic moment for the EB community as the third FDA approved treatment and the first autologous, cell-based gene therapy for RDEB (Recessive Dystrophic Epidermolysis Bullosa). NEW YORK,...
Two studies in the May 29th issue of Cell, a Cell Press publication, have taken advantage of new technological advances to search for and find previously unknown weaknesses in a hard to treat form of cancer. The discoveries lend new hope in the fight again tumors that are today considered...
Plymouth, England – Drugs developed to combat HIV and AIDS are being trialled for the first time in patients with multiple brain tumours. Scientists at the Brain Tumour Research Centre of Excellence at the University of Plymouth are conducting a clinical trial to see whether using anti-retroviral medications, Ritonavir and...
KING OF PRUSSIA, Pa. – Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The approval, based on data from the PATH (Polyneuropathy And Treatment with Hizentra) Extension...
HONG KONG – Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed), and collaborators from the Zhongshan Ophthalmic Centre of Sun Yat-sen University, Guangzhou, have developed a light-activatable prodrug nanomedicine for age-related macular degeneration (AMD) therapy. Through the intravenous injection of the nanomedicine and application...
Hong Kong – A research team led by Professor Anskar Leung Yu-hung, from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has identified PLK4 as a novel therapeutic target for acute myeloid leukaemia (AML) carrying the TP53 mutation. AML is...
Hong Kong – An inter-departmental research team at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) has conducted the world’s first analytic real-world cohort study on the association of clozapine, a highly efficacious antipsychotic drug, with the incidence of blood cancer. Their findings show that the...